Stephen Mandel Argenx Se Put Options Transaction History
Lone Pine Capital LLC
- $12.7 Billion
- Q1 2024
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding ARGX
# of Institutions
356Shares Held
31.3MCall Options Held
212KPut Options Held
210K-
Price T Rowe Associates Inc Baltimore, MD5.5MShares$2.39 Billion0.27% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI3.19MShares$1.38 Billion1.93% of portfolio
-
Janus Henderson Group PLC London, X02.22MShares$963 Million0.49% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD2.12MShares$919 Million0.51% of portfolio
-
Capital World Investors Los Angeles, CA1.86MShares$810 Million0.13% of portfolio
About ARGENX SE
- Ticker ARGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,323,800
- Market Cap $24B
- Description
- argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...